Primary prevention using statins: to be or not to be?

References

• Ford I, et al. West of Scotland Coronary Prevention Study Group. Long-term follow-up of the West of Scotland Coronary Prevention Study. N Engl J Med 2007;357:1477-86
   PubMed Web of Science ®Google Scholar
• Wijeysundera HC, Machado M, Farahati F, et al. Association of temporal trends in risk factors and treatment uptake with coronary heart disease mortality, 1994-2005. JAMA 2010;303:1841-7
   Google Scholar
• Strandberg TE, Pyorala K, Cook TJ, et al. Mortality and incidence of cancer during 10-year follow-up of the Scandinavian Simvastatin Survival Study (4S). Lancet 2004;364:771-7
   PubMed Web of Science ®Google Scholar
• Brugts JJ, Yetgin T, Hoeks SE, et al. The benefits of statins in people without established cardiovascular disease but with cardiovascular risk factors: meta-analysis of randomised controlled trials. BMJ 2009;338:b2376; doi: 10.1136/bmj.b2376
   PubMed Web of Science ®Google Scholar
• Ray KK, Seshasai SRK, Erqou S, et al. Statins and all-cause mortality in high-risk primary prevention: a meta-analysis of 11 randomized controlled trials involving 65 229 participants. Arch Intern Med 2010;170:1024-31
   PubMed Web of Science ®Google Scholar
• Fereneczi EA, Asaria P, Hughes AD, et al. Can a statin neutralize the cardiovascular risk of unhealthy dietary choices? Am J Cardiol 2010;106:587-92
   PubMed Web of Science ®Google Scholar
• Pedersen TR, Kjekshus J, Berg K, et al. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease. Lancet 1994;344:1383-9
   PubMed Web of Science ®Google Scholar
• West of Scotland Coronary Prevention Group. West of Scotland Coronary Prevention Study: identification of high-risk groups and comparison with other cardiovascular intervention trials. Lancet 1996;348:1339-42
   PubMed Web of Science ®Google Scholar
• Skolbekken J-A. Communicating the risk reduction achieved by cholesterol reducing drugs. BMJ 1998;316:1956-8
   PubMed Web of Science ®Google Scholar
• Thavendiranathan P, Bagai A, Brookhart MA, et al. Primary prevention of cardiovascular diseases with statin therapy: a meta-analysis of randomized controlled trials. Arch Intern Med 2006;166:2307-13
   PubMed Web of Science ®Google Scholar
• Kaul S, Morrissey RP, Diamond GA. By Jove! What is a clinician to make of JUPITER? Arch Intern Med 2010;170:1073-7
   PubMed Web of Science ®Google Scholar
• de Lorgeril M, Salen P, Abramson J, et al. Cholesterol lowering, cardiovascular diseases, and the rosuvastatin-JUPITER controversy: a critical reappraisal. Arch Intern Med 2010;170:1032-6
   PubMed Web of Science ®Google Scholar
• Green LA. Cholesterol-lowering therapy for primary prevention: still much we don’t know. Arch Intern Med 2010;170:1007-8
   PubMed Web of Science ®Google Scholar
• Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals. Lancet 2002;360:7-22
   PubMed Web of Science ®Google Scholar
• Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS: Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 1998;279:1615-22
   PubMed Web of Science ®Google Scholar
• Nakamura H, Arakawa K, Itakura H, et al. MEGA Study Group. Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA Study). Lancet 2006;368:1155-63
   PubMed Web of Science ®Google Scholar
• Shepherd J, Cobbe SM, Ford I, et al. West of Scotland Coronary Prevention Study Group. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995;333:1301-7
   PubMed Web of Science ®Google Scholar
• Shepherd J, Blauw GJ, Murphy MB, et al. PROSPER Study Group. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet 2002;360:1623-30
   PubMed Web of Science ®Google Scholar
• Ridker PM, Danielson E, Fonseca FA, et al. JUPITER Study Group. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008;359:2195-207
   PubMed Web of Science ®Google Scholar
• Tziomalos K, Kakafika AI, Athyros VG, et al. The role of statins for the primary and secondary prevention of coronary heart disease in women. Curr Pharm Des 2009;15:1054-62
   PubMed Web of Science ®Google Scholar
• McCullough PA, Verrill TA. Cardiorenal interaction: appropriate treatment of cardiovascular risk factors to improve outcomes in chronic kidney disease. Postgrad Med 2010;122:25-34
   PubMed Web of Science ®Google Scholar
• NEI of NIH. Comparison of AMD treatments trials (CATT): Lucentis-Avastin Trial. A multicenter clinical trial to compare the relative safety and effectiveness of two drugs currently used to treat advanced age-related macular degeneration (AMD). NCT00593450 (The study closed to recruitment earlier this year. Estimated primary completion date is Dec-2010 and final completion date Feb-2012.)
   Google Scholar
• Mundy A. Medicare Eye Study Finds Untapped Savings. Wall Street Journal, 2010
   Google Scholar
• Tufail A, Patel PJ, Egan C, et al. Bevacizumab for neovascular age related macular degeneration (ABC Trial): multicentre randomised double masked study. BMJ 2010;340:c2459
   PubMed Web of Science ®Google Scholar
• Breimer LH, Mikhailidis DP. Statins and primary prevention. Arch Intern Med [2010] in press
   Google Scholar
• MHRA, 2003. Consultation document ARM 18. Request to reclassify a product from POM to P [online]. Available at: http://medicines.mhra.gov.uk/inforesources/publications/arm18.doc
   Google Scholar
• Royal Pharmaceutical Society of Great Britain, 2004. Practice guidance on sale of over-the-counter simvastatin [online]. Available at: http://www.rpsgb.org.uk/pdfs/otcsimvastatinguid.pdf [Accessed 2005-08-04]
   Google Scholar
• Anonymous. Simvastatin over the counter. Drug Ther Bull 2005;43:25-8
   PubMedGoogle Scholar
• Law MR, et al. Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis. BMJ 2003;326:1423-7
   PubMed Web of Science ®Google Scholar
• MHRA 2004. Reclassification summary for simvastatin POM to P. Medicines and Healthcare Products Regulatory Agency. Available at http://medicines.mhra_gov.uk
   Google Scholar
• Jones PH, Davidson MH, Stein EA, et al. for the STELLAR study group. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin and pravastatin across doses (STELLAR Trial). Am J Cardiol 2003;92:152-60
   PubMed Web of Science ®Google Scholar
• Dormuth CR, Patrick AR, Shrank WH, et al. Statin adherence and risk of accidents: a cautionary tale. Circulation 2009;119:2051-7
   PubMed Web of Science ®Google Scholar
• Hansford D, Cunningham S, John D, et al. Community pharmacists’ views, attitudes and early experiences of over-the-counter simvastatin. Pharm World Sci 2007;29:380-5
   PubMed Web of Science ®Google Scholar
• Morrison A. Quoted by Cooper-DeHoff R in Cardiology Today ‘With OTC simvastatin, U.K.'s statin prescriptions down’. May 1, 2007
   Google Scholar
• Filion KB, Delaney AC, Brophy JM, et al. The impact of over-the-counter simvastatin on the number of statin prescriptions in the United Kingdom: a view from the General Practice Research Database. Pharmacoepidemiol Drug Saf 2007;16:1-4
   PubMed Web of Science ®Google Scholar
• Stewart D, Cunningham ITS, Hansford D, et al. General practitioners’ views and experiences of over-the-counter simvastatin in Scotland. Br J Clin Pharmacol 2010;70:356-9. doi: 10.1111/1365-2125.2010.03701
   Google Scholar
• Hung YT, Yeung VTF. Hypothyroidism presenting as hypercholesterolaemia and simvastatin-induced myositis. H K Med J 2000;6:423-4
   Google Scholar
• Thompson PD, Clarkson P, Karas RH. Statin-associated myopathy. JAMA 2003;289:1681-90
   PubMed Web of Science ®Google Scholar
• Bar SL, Holmes DT, Frohlich J. Asymptomatic hypothyroidism and statin-induced myopathy. Can Fam Physician 2007;53:428-31
   PubMed Web of Science ®Google Scholar
• Joy TR, Hegele RA. Statin-related myopathy. Ann Intern Med. 2009;150:858-68
   PubMed Web of Science ®Google Scholar
• Sawin CT. Subclinical hypothyroidism in older persons. Clin Geriatr Med 1995;11:231-8
   PubMed Web of Science ®Google Scholar
• Sundbeck G. Eden S. Jagenburg R., et al. Thyroid dysfunction in 85-year-old men and women. Influence of non-thyroidal illness and drug treatment. Acta Endocrinol 1991;125:475-86
   PubMedGoogle Scholar
• Parle JV, Franklin JA, Cross KW. Prevalence and follow-up of abnormal thyrotropin concentrations in the elderly in the United Kingdom. Clin Endocrinol 1991;34:77-83
   PubMed Web of Science ®Google Scholar
• Bagchi N, Brown TR, Parish RF. Thyroid dysfunction in adults over age 55 years: study in an urban US community. Arch Intern Med 1990;150:785-7
   PubMed Web of Science ®Google Scholar
• Food and Drug Administration 17 Dec 2007. cited in “FDA no to OTC statin”– www.theheart.org/article/833601.do
   Google Scholar
• Tinetti ME. Over-the-counter sales of statins and other drugs for asymptomatic conditions. N Engl J Med 2008;358:2728-32
   PubMed Web of Science ®Google Scholar
• Curtiss FR, Fairman KA. Tough questions about the value of statin therapy for primary prevention: did JUPITER miss the moon? J Manag Care Pharm 2010;16:417-23
   PubMed Web of Science ®Google Scholar
• Bardou M, Barkun A, Martel M. Effect of statin therapy on colorectal cancer. Gut Published on line 2010. doi:10.1136/gut.2009.190900
   Google Scholar
• Hippisley-Cox J, Coupland C. Unintended effects of statins in men and women in England and Wales: population based cohort study using the QResearch database. BMJ 2010;340:c2197
   PubMed Web of Science ®Google Scholar
• Umans-Eckenhausen MA, Defesche JC, et al. Review of first 5 years of screening for familial hypercholesterolaemia in the Netherlands. Lancet 2001;357:165-8
   PubMed Web of Science ®Google Scholar
• van Maarle MC, Stouthard MEA, Bonsel GJ. Quality of life in a family based genetic cascade screening programme for familial hypercholesterolaemia: a longitudinal study among participants. J Med Genet 2003;40:e3-e9
   PubMedGoogle Scholar
• Walldius G, Jungner I, Aastveit AH, et al. The apoB/apoA-I ratio is better than the cholesterol ratios to estimate the balance between plasma proatherogenic and antiatherogenic lipoproteins and to predict coronary risk. Clin Chem Lab Med 2004;42:1355-63
   PubMed Web of Science ®Google Scholar
• Pischon T, Girman CJ, Sacks FM, et al. Non-high-density lipoprotein cholesterol and apolipoprotein B in the prediction of coronary heart disease in men. Circulation 2005;112:3375-83
   PubMed Web of Science ®Google Scholar
• McQueen MJ, et al. Lipids, lipoproteins, and apolipoproteins as risk markers of myocardial infarction in 52 countries (the INTERHEART study): a case-control study. Lancet 2008;372:224-33
   PubMed Web of Science ®Google Scholar
• The Emerging Risk Factors Collaboration (ERFC), Major lipids, apolipoproteins, and risk of vascular disease. JAMA 2009;302:1993-2000
   PubMed Web of Science ®Google Scholar
• Sniderman A, Solhpour A. Targeting targets for LDL-lowering therapy. Clin Chem 2009;55:391-3
   PubMed Web of Science ®Google Scholar
• Gazi IF, Boumpas DT, Mikhailidis DP, et al. Clustering of cardiovascular risk factors in rheumatoid arthritis: the rationale for using statins. Clin Exp Rheumatol 2007;25:102-11
   PubMed Web of Science ®Google Scholar
• Gasparyan AY, Stavropoulos-Kalinoglou A, et al. The rationale for comparative studies of accelerated atherosclerosis in rheumatic diseases. Curr Vasc Pharmacol 2010;8:437-49
   PubMed Web of Science ®Google Scholar
• Tziomalos K, Athyros VG, Karagiannis A, et al. JUPITER: major implications for vascular risk assessment. Curr Med Res Opin 2009;25:133-7
   PubMed Web of Science ®Google Scholar